{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    17,
    18,
    19,
    21,
    24,
    25,
    26,
    27,
    28,
    32,
    35,
    43
  ],
  "modelUsed": "gemini-3-flash-preview",
  "advanced": {
    "studyAmendments": [
      {
        "id": "amend_1",
        "number": "7",
        "name": "Amendment 7",
        "scope": {
          "id": "0ae9df64-6b09-4fac-87a1-0735def1deb3",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "ac23c24b-f306-4e36-9833-d5a4b6802c43",
          "code": {
            "id": "c73e1547-5779-4121-800d-9dc6f80bfaa3",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "89c655c9-a591-4695-a975-baea7bafb01b",
            "type": {
              "id": "897f7829-88cb-4767-8f56-9a9e5c41af01",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "The main purpose of this amendment is to: 1) revise the definition of end of study to include Post-Trial Access (PTA) program i.e rollover protocol or a post study drug supply (PSDS) option for patients still on study treatment and in the opinion of the investigator still deriving clinical benefit at the time of end of the study, 2) update safety information on hemophagocytic lymphohistiocytosis (HLH), and update of 'dose modification and recommended clinical management guidelines' in the safety section including treatment resumption for recurrent grade 4 asymptomatic amylase or lipase elevation per UK Health Authority (MHRA) request.",
        "effectiveDate": "2023-01-27",
        "reasonIds": [
          "ar_1_1",
          "ar_1_2",
          "ar_1_3"
        ],
        "previousVersion": "6",
        "newVersion": "7"
      },
      {
        "id": "amend_2",
        "number": "6",
        "name": "Amendment 6",
        "scope": {
          "id": "d8640d33-5c12-4990-96e4-201c59855dfa",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "0999b055-75c8-4961-9695-98deabaddb99",
          "code": {
            "id": "eefa652b-1222-4def-8dc3-34e3f6f1eaf7",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "014f5652-104d-406a-9630-9399186e3972",
            "type": {
              "id": "623690f2-8af9-4063-a996-a19b4a28c17c",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "Unblinding of study treatment is mandatory and the decision to continue study treatment with PDR001 in combination with dabrafenib and trametinib should be made by the physician on a case by case basis following medical judgement and considering the risk/benefit assessment upon discussion with the patient. Placebo administrations to those patients randomized to the placebo arm will stop. Furthermore, this protocol amendment will also incorporate the removal of the crossover schedule as this is no longer applicable as protocol defined criteria for crossover was not met and inclusion of guidance on coronavirus disease-19 (COVID-19) related challenges.",
        "effectiveDate": "2020-10-13",
        "reasonIds": [
          "ar_2_1",
          "ar_2_2",
          "ar_2_3"
        ],
        "previousVersion": "5",
        "newVersion": "6"
      },
      {
        "id": "amend_3",
        "number": "5",
        "name": "Amendment 5",
        "scope": {
          "id": "3bef6897-3472-4cd8-837b-4dbf7a685b37",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "d010c8de-376a-47e4-b88c-d03c5860fd62",
          "code": {
            "id": "36a53886-7ff3-40df-b192-df4aea204b18",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "a419a631-213e-4e32-a6d1-8a7001b93b75",
            "type": {
              "id": "1fb0be37-8859-4d47-89e3-fbf2cc1d7798",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "The primary objective of this protocol amendment is to adjust the timing of the final PFS analysis and to include an interim analysis for PFS based on revised assumptions on the delayed treatment effect. The original trial design assumed a delayed treatment effect of 1.5 months for PFS and of 3 months for OS; however, a delayed treatment effect of 5 months for PFS was observed in the KEYNOTE-022 trial in a similar patient population.",
        "effectiveDate": "2019-03-08",
        "reasonIds": [
          "ar_3_1",
          "ar_3_2"
        ],
        "previousVersion": "4",
        "newVersion": "5"
      },
      {
        "id": "amend_4",
        "number": "4",
        "name": "Amendment 4",
        "scope": {
          "id": "70045993-f041-4642-bd39-7537791bdf7d",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "b65f777a-d6ea-4d7e-a829-493000c4258f",
          "code": {
            "id": "65687225-2d02-4383-a2d4-94e42519bff5",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "9d019512-8ab4-44dd-be1c-6d4060e444ef",
            "type": {
              "id": "89e2f6bd-5250-43ba-9569-6c12cd36e6c9",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "The primary objective of this protocol amendment is to align the contraception requirements during and after study treatment based on the dabrafenib Investigator’s Brochure (IB) Edition 10 and trametinib IB Edition 9. Further, the safety follow-up periods have been aligned with the contraception requirements after study treatment has been discontinued.",
        "effectiveDate": "2018-08-14",
        "reasonIds": [
          "ar_4_1",
          "ar_4_2",
          "ar_4_3"
        ],
        "previousVersion": "3",
        "newVersion": "4"
      },
      {
        "id": "amend_5",
        "number": "3",
        "name": "Amendment 3",
        "scope": {
          "id": "11c8ded3-812d-4c22-b762-9e3a63c62838",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "e25cd0f5-f2ea-4da3-83c1-1e7ee2b79d74",
          "code": {
            "id": "59c6c87d-a6f4-4e6b-971e-12cbfe5b41e6",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "ce50eecb-08ba-4c36-8fbf-d8889b0aad8b",
            "type": {
              "id": "e1be17e8-1901-4690-86b3-d75cbab9905f",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "The primary objective of this protocol amendment is to change pyrexia management guidelines based on the safety profile observed in the safety run-in (part 1) and feedback received from investigators upon review of safety data. At the same time, changes to improve data collection for radiotherapy events, central review using tumor response criteria based on guidelines for immunotherapy, ophthalmologic examination assessment frequency, and patient reported outcomes are implemented.",
        "effectiveDate": "2017-07-14",
        "reasonIds": [
          "ar_5_1",
          "ar_5_2",
          "ar_5_3"
        ],
        "previousVersion": "2",
        "newVersion": "3"
      },
      {
        "id": "amend_6",
        "number": "2",
        "name": "Amendment 2",
        "scope": {
          "id": "ce0debf1-fd1c-4ab5-8abd-c9ec7d8228c3",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "953ec1a4-6d6f-481e-b8ff-727ca5a30f3b",
          "code": {
            "id": "e00dc7f1-d123-4c63-8648-63120c85f836",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "6ddcf5a7-9626-4e66-a7e2-f576c969ffb3",
            "type": {
              "id": "f297af24-1cd7-4875-951d-b8d9697a1230",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "Amendment 2 (substantial amendment) is required to implement specific feedback received from the U.S. Food and Drug Administration (FDA) and the German Paul-Ehrlich Institute (PEI) and the French health authority ANSM (agence nationale de sécurité du medicament) upon review of the protocol.",
        "effectiveDate": "2017-03-07",
        "reasonIds": [
          "ar_6_1",
          "ar_6_2"
        ],
        "previousVersion": "1",
        "newVersion": "2"
      },
      {
        "id": "amend_7",
        "number": "1",
        "name": "Amendment 1",
        "scope": {
          "id": "e0bd592d-036e-4728-9eae-a5f4bf28856f",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "33fc827d-3389-413d-946c-da2c384e92a8",
          "code": {
            "id": "eff623f0-daac-4a64-928a-57bfa160ef2b",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "93f56258-b259-4c8c-aaa3-a996ce47dfd9",
            "type": {
              "id": "df2b7fda-b45f-42f4-b4b3-48f8e03210b7",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "The primary purpose of this protocol amendment is to clarify that double barrier contraception methods are not classified as highly effective methods, per Clinical Trial Facilitation Group (CTFG) guidelines.",
        "effectiveDate": "2017-01-27",
        "reasonIds": [
          "ar_7_1",
          "ar_7_2"
        ],
        "previousVersion": "Original Protocol",
        "newVersion": "1"
      }
    ],
    "amendmentReasons": [
      {
        "id": "ar_1_1",
        "code": "OPERATIONAL",
        "description": "Operational",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_1_2",
        "code": "REGULATORY",
        "description": "Regulatory",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_1_3",
        "code": "SAFETY",
        "description": "Safety",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_2_1",
        "code": "SCIENTIFIC",
        "description": "Scientific",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_2_2",
        "code": "OPERATIONAL",
        "description": "Operational",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_2_3",
        "code": "SAFETY",
        "description": "Safety",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_3_1",
        "code": "SCIENTIFIC",
        "description": "Scientific",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_3_2",
        "code": "STATISTICAL",
        "description": "Statistical",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_4_1",
        "code": "SAFETY",
        "description": "Safety",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_4_2",
        "code": "REGULATORY",
        "description": "Regulatory",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_4_3",
        "code": "ADMINISTRATIVE",
        "description": "Administrative",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_5_1",
        "code": "SAFETY",
        "description": "Safety",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_5_2",
        "code": "OPERATIONAL",
        "description": "Operational",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_5_3",
        "code": "SCIENTIFIC",
        "description": "Scientific",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_6_1",
        "code": "REGULATORY",
        "description": "Regulatory",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_6_2",
        "code": "SAFETY",
        "description": "Safety",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_7_1",
        "code": "REGULATORY",
        "description": "Regulatory",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_7_2",
        "code": "SAFETY",
        "description": "Safety",
        "instanceType": "AmendmentReason"
      }
    ],
    "countries": [
      {
        "id": "country_1",
        "name": "United States",
        "instanceType": "Country",
        "code": "US"
      },
      {
        "id": "country_2",
        "name": "Germany",
        "instanceType": "Country",
        "code": "DE"
      },
      {
        "id": "country_3",
        "name": "France",
        "instanceType": "Country",
        "code": "FR"
      },
      {
        "id": "country_4",
        "name": "Switzerland",
        "instanceType": "Country",
        "code": "CH"
      },
      {
        "id": "country_5",
        "name": "United Kingdom",
        "instanceType": "Country",
        "code": "GB"
      }
    ],
    "studySites": [],
    "summary": {
      "amendmentCount": 7,
      "countryCount": 5,
      "siteCount": 0
    },
    "geographicScope": {
      "id": "geo_1",
      "name": "Study Geographic Scope",
      "scopeType": "Global",
      "instanceType": "GeographicScope",
      "countryIds": [
        "country_1",
        "country_2",
        "country_3",
        "country_4",
        "country_5"
      ],
      "regions": [
        "North America",
        "Europe"
      ]
    }
  },
  "rawResponse": {
    "amendments": [
      {
        "number": "7",
        "effectiveDate": "2023-01-27",
        "summary": "The main purpose of this amendment is to: 1) revise the definition of end of study to include Post-Trial Access (PTA) program i.e rollover protocol or a post study drug supply (PSDS) option for patients still on study treatment and in the opinion of the investigator still deriving clinical benefit at the time of end of the study, 2) update safety information on hemophagocytic lymphohistiocytosis (HLH), and update of 'dose modification and recommended clinical management guidelines' in the safety section including treatment resumption for recurrent grade 4 asymptomatic amylase or lipase elevation per UK Health Authority (MHRA) request.",
        "previousVersion": "6",
        "newVersion": "7",
        "reasons": [
          "Operational",
          "Regulatory",
          "Safety"
        ]
      },
      {
        "number": "6",
        "effectiveDate": "2020-10-13",
        "summary": "Unblinding of study treatment is mandatory and the decision to continue study treatment with PDR001 in combination with dabrafenib and trametinib should be made by the physician on a case by case basis following medical judgement and considering the risk/benefit assessment upon discussion with the patient. Placebo administrations to those patients randomized to the placebo arm will stop. Furthermore, this protocol amendment will also incorporate the removal of the crossover schedule as this is no longer applicable as protocol defined criteria for crossover was not met and inclusion of guidance on coronavirus disease-19 (COVID-19) related challenges.",
        "previousVersion": "5",
        "newVersion": "6",
        "reasons": [
          "Scientific",
          "Operational",
          "Safety"
        ]
      },
      {
        "number": "5",
        "effectiveDate": "2019-03-08",
        "summary": "The primary objective of this protocol amendment is to adjust the timing of the final PFS analysis and to include an interim analysis for PFS based on revised assumptions on the delayed treatment effect. The original trial design assumed a delayed treatment effect of 1.5 months for PFS and of 3 months for OS; however, a delayed treatment effect of 5 months for PFS was observed in the KEYNOTE-022 trial in a similar patient population.",
        "previousVersion": "4",
        "newVersion": "5",
        "reasons": [
          "Scientific",
          "Statistical"
        ]
      },
      {
        "number": "4",
        "effectiveDate": "2018-08-14",
        "summary": "The primary objective of this protocol amendment is to align the contraception requirements during and after study treatment based on the dabrafenib Investigator’s Brochure (IB) Edition 10 and trametinib IB Edition 9. Further, the safety follow-up periods have been aligned with the contraception requirements after study treatment has been discontinued.",
        "previousVersion": "3",
        "newVersion": "4",
        "reasons": [
          "Safety",
          "Regulatory",
          "Administrative"
        ]
      },
      {
        "number": "3",
        "effectiveDate": "2017-07-14",
        "summary": "The primary objective of this protocol amendment is to change pyrexia management guidelines based on the safety profile observed in the safety run-in (part 1) and feedback received from investigators upon review of safety data. At the same time, changes to improve data collection for radiotherapy events, central review using tumor response criteria based on guidelines for immunotherapy, ophthalmologic examination assessment frequency, and patient reported outcomes are implemented.",
        "previousVersion": "2",
        "newVersion": "3",
        "reasons": [
          "Safety",
          "Operational",
          "Scientific"
        ]
      },
      {
        "number": "2",
        "effectiveDate": "2017-03-07",
        "summary": "Amendment 2 (substantial amendment) is required to implement specific feedback received from the U.S. Food and Drug Administration (FDA) and the German Paul-Ehrlich Institute (PEI) and the French health authority ANSM (agence nationale de sécurité du medicament) upon review of the protocol.",
        "previousVersion": "1",
        "newVersion": "2",
        "reasons": [
          "Regulatory",
          "Safety"
        ]
      },
      {
        "number": "1",
        "effectiveDate": "2017-01-27",
        "summary": "The primary purpose of this protocol amendment is to clarify that double barrier contraception methods are not classified as highly effective methods, per Clinical Trial Facilitation Group (CTFG) guidelines.",
        "previousVersion": "Original Protocol",
        "newVersion": "1",
        "reasons": [
          "Regulatory",
          "Safety"
        ]
      }
    ],
    "geographicScope": {
      "type": "Global",
      "countries": [
        {
          "name": "United States",
          "code": "US"
        },
        {
          "name": "Germany",
          "code": "DE"
        },
        {
          "name": "France",
          "code": "FR"
        },
        {
          "name": "Switzerland",
          "code": "CH"
        },
        {
          "name": "United Kingdom",
          "code": "GB"
        }
      ],
      "regions": [
        "North America",
        "Europe"
      ],
      "plannedSites": null
    },
    "sites": []
  }
}